Cardiogenic shock complicating acute coronary syndromes

David Hasdai, Eric J. Topol, Robert M. Califf, Peter B. Berger, David R. Holmes

Research output: Contribution to journalReview article

127 Scopus citations

Abstract

Cardiogenic shock remains the major cause of death among patients with all types of acute coronary syndromes. Thus, there is a growing interest in the identification of patients who are at risk for developing cardiogenic shock, in the exploration of different therapeutic approaches to preventing its development, and in the improvement of outcome when it occurs. This article reviews the aetiology and pathophysiology of cardiogenic shock, its epidemology, Its treatment (including pharmaceutical agents, counterpulsation, and revascularisation), and its outcome. Algorithms are presented that predict its occurrence in both ST-segment-elevation myocardial infarction and unstable angina or non-ST-elevation myocardial infarction, and that predict its mortality in patients with ST-segment-elevation acute myocardial infarction. Such new areas as metabolic therapy and glycopretein IIb/IIIa inhibitors are discussed, as are the economic implications of shock.

Original languageEnglish (US)
Pages (from-to)749-756
Number of pages8
JournalLancet
Volume356
Issue number9231
DOIs
StatePublished - Aug 26 2000

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hasdai, D., Topol, E. J., Califf, R. M., Berger, P. B., & Holmes, D. R. (2000). Cardiogenic shock complicating acute coronary syndromes. Lancet, 356(9231), 749-756. https://doi.org/10.1016/S0140-6736(00)02640-4